Clinical Trials Logo

Blood Coagulation Disorders clinical trials

View clinical trials related to Blood Coagulation Disorders.

Filter by:

NCT ID: NCT04115722 Not yet recruiting - Coagulopathy Clinical Trials

Coagulation Parameters in IBD Patients

Start date: November 2019
Phase:
Study type: Observational

1. to assess the incidence of coagulation disorders in IBD patients in comparison with another normal controlled group 2. risk factors that contribute to development of thrombosis in IBD patients 3. to determine the effectiveness of prophlactive anticoagulant measures 4. to determine the association between disease activity and coagulation parameters

NCT ID: NCT04111120 Recruiting - Cirrhosis, Liver Clinical Trials

Heparin Like Effect in Acute Variceal Bleeding

Start date: November 1, 2019
Phase:
Study type: Observational

This study attempts to clarify the pathophysiology of haemostasis in relation to the evidence of sepsis in liver disease, and compares the accuracy of various available laboratory tests in assessment of these patients. Further research is needed for proper understanding of the influence of sepsis on coagulation disorders in acute variceal bleeding in cirrhosis, to correctly identify the type and optimal quantity of blood product requirement in at risk patients. Thromboelastography (TEG) /Sonoclot has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products. Secondly, the study of derangement in coagulopathy after the onset of sepsis is of paramount importance because of increased mortality after the onset of sepsis. In the present study, patients with cirrhosis who present with acute variceal bleeding, will be included in the study cohort, and will undergo a baseline diagnostic workup as described. They will be followed for development of any signs of infection after hospitalization. Then the effect of sepsis on their coagulation and thrombin generation response swill be assessed. Thus the effect of sepsis on the progression and outcome of coagulopathy in patients with acute variceal bleeding will be studied.

NCT ID: NCT04107818 Completed - Clinical trials for Coagulation Disorder

Comparison of Viscoelastic Measurement by ROTEM® Delta and ClotPro® in Trauma Patients.

ROTCLOT
Start date: November 21, 2019
Phase:
Study type: Observational

The purpose of the study is to describe the differences and interchangeability in measurements of viscoelastic tests of coagulation by two different devices in adult trauma patients.

NCT ID: NCT04076605 Completed - Bleeding Clinical Trials

Bleeding in Hospitalized Patients With Liver Disease Undergoing Invasive Procedures

PROC-BLeeD
Start date: November 15, 2019
Phase:
Study type: Observational

Patients with cirrhosis are frequently hospitalized and often undergo procedures. Knowledge surrounding bleeding risk is sparse and practice patterns vary across centers in regards to bleeding prophylaxis. The goal of this study to is to obtain more knowledge regarding risk factors for procedural related bleeding in patients with cirrhosis and to develop a predictive model to risk stratify patients before undergoing procedures. Through collaboration from centers across the world this study should provide information on prevalence of bleeding and variation in practice patterns for prophylaxis.

NCT ID: NCT04074980 Completed - Clinical trials for Anticoagulants and Bleeding Disorders

Evaluation of the Accuracy of INR Results From Patients Taking Phenprocoumon as Anticoagulant When Measured Using the Lumiradx INR Test

VKA GERMANY
Start date: May 9, 2019
Phase: N/A
Study type: Interventional

This study is to evaluate the INR levels in patients taking phenprocoumon using the LumiraDx Point of Care INR test and comparing the results to the laboratory reference method , the ACL Elite Pro. Comparison will also be made with the Roche Coaguchek point of care INR test (point of care reference method). Performance will be demonstrated across a subject population of adult males and females in receipt of Phenprocoumon VKA therapy. This population is representative of the indications for use of the CE marked product. Operators will be trained clinical site staff. Venous plasma and capillary whole blood samples will be obtained from each subject in order to assess accuracy of the the LumiraDx Platform when compared to the reference devices (ACL Elite and Coaguchek Pro).

NCT ID: NCT04046029 Recruiting - Aging Clinical Trials

Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.

Start date: July 8, 2019
Phase: Phase 4
Study type: Interventional

The study is an investigator-sponsored, prospective, multicenter, randomized, open-label study designed to compare efficacy and safety between bivalirudin and heparin in elderly patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.

NCT ID: NCT03993977 Withdrawn - Clinical trials for Blood Loss, Surgical

ROTEM-guided Transfusion Protocol in Attempt to Reduce Blood Transfusions in Major Oncological Surgery

ROTEM-SUR
Start date: May 1, 2020
Phase: N/A
Study type: Interventional

Need for perioperative blood transfusion is still high in certain types of oncological abdominal surgery. Allogeneic blood transfusion may be detrimental in cancer patients undergoing a potentially curative resection of malignant tumor, although the detailed mechanism of this effect is still under debate. We plan to evaluate whether a new, rotational thromboelastography-guided algorithm (ROTEM) to guide hemostatic resuscitation intra-operatively decreases the use of allogeneic blood products, the total amount of bleeding, transfusion related side effects, thromboembolic complications and costs. Its effect on each patient's post-operative hemostatic profile is also measured. 60 patients having a potentially curative pancreaticoduodenectomy (or resection of cauda of pancreas), total removal or partial resection of kidney and open radical cystectomy are recruited when an active blood loss of more than 1500 ml is estimated and/or measured and are randomized into two groups: one will be treated conventionally, ie. using massive transfusion protocol (MTP) if necessary, clinical judgement and conventional coagulation tests, the other treated using a ROTEM-based algorithm.

NCT ID: NCT03981484 Not yet recruiting - Hemorrhage Clinical Trials

REPlaCE- Randomized Trial Evaluating the Use of Prothrombin Complex concEntrate to Improve Survival in Patients With Traumatic Coagulopathy

REPLaCE
Start date: January 2020
Phase: Phase 2
Study type: Interventional

Uncontrolled hemorrhage continues to be a significant source of mortality for trauma patients. Their condition is further complicated by Trauma Induced Coagulopathy (TIC), which makes it more difficult to control bleeding due to coagulation factor deficiency. Prothrombin Complex Concentrate (PCC) is thought to be a promising treatment option. This phase II clinical trial evaluates the use of 4-Factor PCC in addition to standard resuscitation methods compared to standard resuscitation methods alone in patients with TIC. Patients will be randomized at a 1:1 ratio. The primary endpoint of this trial will be 30 day mortality.

NCT ID: NCT03972839 Completed - Clinical trials for Blood Coagulation Disorder

Comparison of Two D-Dimers Dosing Techniques

COMPADDI
Start date: July 1, 2019
Phase:
Study type: Observational

Study of the possibility of substitution of the automated STAGO D-Dimers method with the semi-automated VIDAS method, which is more expensive, longer to implement and requires the use of a dedicated automaton.

NCT ID: NCT03962400 Withdrawn - Clotting Disorder Clinical Trials

Reinforcement Learning for Warfarin Dosing

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

This is a clinical study designed to test the hypothesis that a computer model for dosing warfarin is superior to current clinical practice. Subjects will be randomized to two groups based on how warfarin dose is determined and followed for 6 months. The primary outcome is the percent of the time that the INR is maintained in the effective range.